Merck will continue to support AIDS Drug Assistance Programs
In the new deal, Merck will provide continued support for initiatives to provide low-income individuals living with HIV with access to medicines. Merck will also give access for eligible ADAPs to obtain ISENTRESS film-coated tablets at the January 2012 price. Finally, Merck will add a "frozen" low price to eligible ADAPs for ISENTRESS chewable tablets for the treatment of HIV-1 infection in children and adolescents two years of age and older.
"Merck has steadfastly supported the ACTF since 2002. We are proud to reaffirm our long-standing commitment to ADAPs and their mission to help people living with HIV," Chirfi Guindo, vice president and general manager of Merck, said. "ADAPs continue to experience fiscal instability as a result of a changing healthcare system. By working together as partners - government, community and industry - we can help to support these critical state programs, and help provide access to medicines for uninsured and underserved HIV patients."
ADAPs are estimated to reach about one-third of people with HIV in the United States. Merck has contributed to the ADAP program 3 other times in the past and was also the first company to freeze the price of an antiretroviral therapy.
ISENTRESS is an integrase inhibitor used to treat and control HIV-1. ISENTRESS does not cure HIV-1 or AIDS.